GSK Dodges Putative Class Claims Over Avandia Payments

Law360, Philadelphia (July 12, 2013, 4:15 PM EDT) -- A Pennsylvania federal judge on Wednesday tossed out four putative class actions against GlaxoSmithKline PLC, in which the plaintiffs sought refunds of the co-pays and other money they spent on purchasing the diabetes treatment drug Avandia.

U.S. District Judge Cynthia Rufe found that each of the four suits — which individually asserted claims under California, New Jersey, New York and Pennsylvania law — failed to demonstrate that the plaintiffs had been harmed by the pharmaceutical giant’s marketing efforts.

The judge dismissed all four suits with prejudice....
To view the full article, register now.